Traders Purchase Large Volume of Adaptimmune Therapeutics Call Options (NASDAQ:ADAP)

Adaptimmune Therapeutics PLC (NASDAQ:ADAP) was the target of some unusual options trading activity on Friday. Stock traders bought 3,772 call options on the stock. This is an increase of 853% compared to the average daily volume of 396 call options.

Insider Buying and Selling

In related news, Director Ali Behbahani sold 14,671,794 shares of the stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $0.01, for a total transaction of $146,717.94. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold 19,803,000 shares of company stock worth $198,030 over the last ninety days. 12.74% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Adaptimmune Therapeutics

Several institutional investors have recently modified their holdings of the business. Long Focus Capital Management LLC grew its position in shares of Adaptimmune Therapeutics by 15.9% during the 1st quarter. Long Focus Capital Management LLC now owns 23,756,687 shares of the biotechnology company’s stock worth $4,680,000 after buying an additional 3,262,294 shares during the period. Two Seas Capital LP grew its position in shares of Adaptimmune Therapeutics by 10.0% during the 2nd quarter. Two Seas Capital LP now owns 22,580,701 shares of the biotechnology company’s stock worth $5,413,000 after buying an additional 2,051,016 shares during the period. Acadian Asset Management LLC grew its position in shares of Adaptimmune Therapeutics by 334.8% during the 1st quarter. Acadian Asset Management LLC now owns 2,218,215 shares of the biotechnology company’s stock worth $424,000 after buying an additional 1,707,999 shares during the period. Empirical Finance LLC acquired a new stake in shares of Adaptimmune Therapeutics during the 2nd quarter worth approximately $192,000. Finally, Jane Street Group LLC grew its position in shares of Adaptimmune Therapeutics by 87.7% during the 4th quarter. Jane Street Group LLC now owns 326,937 shares of the biotechnology company’s stock worth $176,000 after buying an additional 152,780 shares during the period. Institutional investors and hedge funds own 31.37% of the company’s stock.

Adaptimmune Therapeutics Trading Down 9.8%

ADAP opened at $0.14 on Friday. The company has a current ratio of 1.52, a quick ratio of 1.29 and a debt-to-equity ratio of 4.24. The stock has a market capitalization of $38.27 million, a PE ratio of -0.22 and a beta of 2.24. Adaptimmune Therapeutics has a 1-year low of $0.04 and a 1-year high of $1.03. The firm has a 50-day moving average price of $0.12 and a two-hundred day moving average price of $0.23.

Adaptimmune Therapeutics (NASDAQ:ADAP) last posted its quarterly earnings data on Wednesday, August 13th. The biotechnology company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.04. Adaptimmune Therapeutics had a negative net margin of 260.82% and a negative return on equity of 163.73%. The firm had revenue of $13.68 million during the quarter, compared to analysts’ expectations of $11.04 million. As a group, equities analysts anticipate that Adaptimmune Therapeutics will post -0.14 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently commented on ADAP shares. Mizuho downgraded shares of Adaptimmune Therapeutics from an “outperform” rating to a “neutral” rating and reduced their price target for the company from $1.50 to $0.50 in a research report on Thursday, June 26th. Guggenheim downgraded shares of Adaptimmune Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 29th. Finally, HC Wainwright restated a “neutral” rating on shares of Adaptimmune Therapeutics in a research report on Tuesday, July 29th. One analyst has rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $1.35.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.